Trials / Terminated
TerminatedNCT03941834
Trial for Treatment Refractory Trigeminal Neuralgia
BHV3000-202: Phase 2: A Double-Blind, Placebo Controlled, Crossover Trial of BHV-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | BHV3000 (rimegepant) 75mg tablet |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2019-06-25
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
- First posted
- 2019-05-08
- Last updated
- 2024-06-10
- Results posted
- 2024-06-10
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03941834. Inclusion in this directory is not an endorsement.